EP
LUMO

Eversept Partners’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Eversept Partners’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-30,331
Closed -$434K – 77
2019
Q3 		$434K Buy
+30,331
New +$445K 0.13% 51

Other funds holding LUMO

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Eversept Partners's LUMO Position: Q4 2019 in Review

Eversept Partners sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2019, closing a stake of 30,331 shares — an estimated $434K sold.

Eversept Partners first reported a position in LUMO in Q3 2019 and held it in 1 quarter. The position peaked at $434K in Q3 2019. 64 funds tracked by Wall St. Rank hold LUMO as of Q4 2019.

  • Eversept Partners reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Eversept Partners sold 30,331 Lumos Pharma, Inc. Common Stock shares in Q4 2019, an estimated $434K.
  • Eversept Partners first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Eversept Partners's Lumos Pharma, Inc. Common Stock position peaked at $434K in Q3 2019.
  • 64 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2019.

Based on Eversept Partners's 13F filing for Q4 2019, filed 13 Feb 2020.